Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
editorial
. 2016 Feb 1;7:9. doi: 10.3389/fphar.2016.00009

Editorial: 5-HT2A/2B/2C Receptors, Memory, and Neuropsychiatric Disorders

Antonella Gasbarri 1, Bettina Bert 2, Alfredo Meneses 3,*
PMCID: PMC4734106  PMID: 26869926

It is very well known that memory formation and forgetting represent important cognitive functions modulated by several neurotransmitters, including serotonin (5-hydroxytryptamine, 5-HT) (e.g., Fioravanti and Di Cesare, 1992; Wagner and Davachi, 2001; Wixted, 2004; Mansuy, 2005; Hardt et al., 2013; Hupbach; Callaghan et al., 2014; Li et al., 2015; Meneses), and memory dysfunction is present in several neuropsychiatric disorders (Meyer-Lindenberg et al., 2012; Millan et al., 2012, 2014). How does the brain become dysfunctional? Such a question has intrigued neuroscientists for many years. Over recent decades, neuroscience research has shed light on this complex issue and growing evidence is providing important insights. For instance, several lines of evidence demonstrate that dysfunctions in memory processes occur in several neuropsychiatric disorders, including Alzheimer's disease (AD), characterized by memory deficits and dementia; however, dysfunctional memory is observed in other age-related neurodegenerative disorders, such as schizophrenia, post-traumatic stress disorder, stroke, etc. (Millan et al., 2014; Hashimoto, 2015). So far, no effective treatment for dysfunctional memory exists (e.g., Millan et al., 2012, 2014; Sun et al., 2015); this area is hampered by the absence of neural markers associated to memory. Hence, progress in the fields relating to memory, amnesia, forgetting (e.g., Tellez et al., 2012) and AD (e.g., McConathy and Sheline, 2015; Muenchhoff et al., 2015; Scarr et al., 2015) as well as mild cognitive impairment (Eshkoor et al., 2015) would be facilitated considerably by identification of suitable neural markers. Serotonin is involved in several physiological and pathophysiological processes in mammals and in the treatment of psychiatric disorders (Meneses). It is very well known that 5-HT receptor heterogeneity allows for greater advances, and 5-HT 2A∕2B∕2C receptors are emerging as important tools for preclinical and clinical investigation. This special issue provides a deep overview of important advances on cerebral modifications associated with neuropsychiatric alterations, including dysfunctional memory. In particular, some papers analyse the role of serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia (Sumiyoshi et al.), while others are focused on the missing link of the central serotonin-2A 5-HT2A receptor dysfunction in depression and epilepsy (Guiard and Di Giovanni) and on the activity-regulated cytoskeleton-associated protein's putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression is presented (Li et al.). Moreover, a critical evaluation of serotonin mediation of early memory formation via 5-HT2B receptor-induced glycogenolysis in the day-old chick is provided (Gibbs and Hertz). An important subject is the neuronal localization of the 5-HT2 receptor family in the amygdaloid complex and emotion memories (Bombardi). Modeling dysfunctional memory, mitochondrial energy metabolism in different regions of the brain and potential treatments is illustrated (Singh and Kumar). In short, the translational feature of this special issue may expand our knowledge on brain dysfunctions and inspire further investigation, thus leading to a better management of psychiatric diseases.

Author contributions

AG wrote the editorial. AM revised and corrected the manuscript. BB worked as referee.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Callaghan B. L., Li S., Richardson R. (2014). The elusive engram: what can infantile amnesia tell us about memory? Trends Neurosci. 37, 47–53. 10.1016/j.tins.2013.10.007 [DOI] [PubMed] [Google Scholar]
  2. Eshkoor S. A., Hamid T. A., Mun C. Y., Ng C. K. (2015). Document mild cognitive impairment and its management in older people. Clin. Interv. Aging 10, 687–693. 10.2147/CIA.S73922 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fioravanti M., Di Cesare F. (1992). Forgetting curves in long-term memory: evidence for a multistage model of retention. Brain Cogn. 18, 116–124. 10.1016/0278-2626(92)90073-U [DOI] [PubMed] [Google Scholar]
  4. Hardt O., Nader K., Nadel L. (2013). Decay happens: the role of active forgetting in memory. Trends Cogn. Sci. 17, 111–120. 10.1016/j.tics.2013.01.001 [DOI] [PubMed] [Google Scholar]
  5. Hashimoto K. (2015). Tropisetron and its targets in Alzheimer's disease. Expert Opin. Ther. Targets 19, 1–5. 10.1517/14728222.2014.983901 [DOI] [PubMed] [Google Scholar]
  6. Li L. B., Zhang L., Sun Y. N., Han L. N., Wu Z. H., Zhang Q. J., et al. (2015). Activation of serotonin2A receptors in the medial septum-diagonal band of Broca complex enhanced working memory in the hemiparkinsonian rats. Neuropharmacology 91, 23–33. 10.1016/j.neuropharm.2014.11.025 [DOI] [PubMed] [Google Scholar]
  7. Mansuy I. M. (2005). Forgetting: theories and potential mechanisms. Med. Sci. 21, 83–88. 10.1051/medsci/200521183 [DOI] [PubMed] [Google Scholar]
  8. McConathy J., Sheline Y. I. (2015). Imaging biomarkers associated with cognitive decline: a review. Biol. Psychiatry 77, 685–692. 10.1016/j.biopsych.2014.08.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Meyer-Lindenberg A., Murphy D., Rolls E., Saletu B., Spedding M., Sweeney J., et al. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 1, 141–168. 10.1038/nrd3628 [DOI] [PubMed] [Google Scholar]
  10. Millan M. J., Agid Y., Brune M., Bullmore E. T., Carter C. S., Clayton N. S., et al. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug. Discov. 11, 141–168. 10.1038/nrd3628 [DOI] [PubMed] [Google Scholar]
  11. Millan M. J., Agid Y., Brüne M., Bullmore E. T., Carter C. S., Clayton N. S., et al. (2014). The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement. 10, 808–817. 10.1016/j.jalz.2014.03.003 [DOI] [PubMed] [Google Scholar]
  12. Muenchhoff J., Poljak A., Song F., Raftery M., Brodaty H., Duncan M., et al. (2015). Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts. J. Alzheimers Dis. 43, 1355–1373. 10.3233/JAD-141266 [DOI] [PubMed] [Google Scholar]
  13. Scarr E., Millan M. J., Bahn S., Bertolino A., Turck C. W., Kapur S., et al. (2015). Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP Think Tank. Int. J. Neuropsychopharmacol. 18:pyv042. 10.1093/ijnp/pyv042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sun M. K., Nelson T. J., Alkon D. L. (2015). Towards universal therapeutics for memory disorders. Trends Pharmacol. Sci. 36, 384–394. 10.1016/j.tips.2015.04.004 [DOI] [PubMed] [Google Scholar]
  15. Tellez R., Gómez-Viquez L., Liy-Salmeron G., Meneses A. (2012). GABA, glutamate, dopamine and serotonin transporters expression on forgetting. Neurobiol. Learn. Mem. 98, 66–77. 10.1016/j.nlm.2012.05.001 [DOI] [PubMed] [Google Scholar]
  16. Wagner A., Davachi L. (2001). Cognitive neuroscience: forgetting of things past. Curr. Biol. 11, R964–R967. 10.1016/S0960-9822(01)00575-9 [DOI] [PubMed] [Google Scholar]
  17. Wixted J. T. (2004). The psychology and neuroscience of forgetting. Annu. Rev. Psychol. 55, 235–269. 10.1146/annurev.psych.55.090902.141555 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES